Element Biosciences, Inc. today announced that the Regional Court of Munich I (Landgericht München I) has ruled that Illumina, Inc. and its German subsidiary, Illumina GmbH, infringe patent rights ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

It happens in Hollywood and on Broadway: Sometimes a great production wins mostly positive reviews from the critics but fails to wow the audience. The critics here are analysts, who largely applauded ...

Illumina is suing Element Biosciences, with the sequencing giant accusing its smaller rival of infringing on five of its patents covering flow cell and imaging technologies used in automated genetic ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced MiSeq™, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that its MiSeq™Dx Sequencing System received the approval certificate from the China National Drug Administration (CNDA). This ...

The Illumina MiSeq stands out as a robust desktop sequencing system ideal for targeted applications such as amplicon sequencing, small genome sequencing, metagenomics, miRNA-seq, targeted gene ...

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc.’s (NASDAQ: ILMN) NextSeq™ 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq™Dx which ...